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Cationic peptides termed protein transduction domains (PTDs) have been shown to cross biological membranes eﬃciently.
However, proteins transduced by PTDs become entrapped within the endosomal vesicles and are not delivered into organelles.
We have developed a novel protein delivery system to enhance the proton sponge eﬀect, which results in rupture of the endosomes,
by using a mixture of Wr-T transporter peptide and a commercially available cationic lipid reagent. This peptide and cationic lipid
reagent mixture eﬃciently delivers a variety of cargo proteins into living cells by releasing them from the endosomes.
1.Introduction
Protein transduction technology has the potential to con-
stitute a useful tool for studying proteomics. Protein trans-
duction domains (PTDs) such as HIV-1 TAT, pAntp43-58,
and polyarginine (R9) are small peptides that are able to
transduce a variety of peptides and proteins into several
kinds of cells [1–3].
However, protein transduction technology using PTDs
has the disadvantage of entrapping the PTD-fused protein
within the endosomal vesicles. It has been reported that the
main mechanism of protein transduction is the penetration
into cells by macropinocytosis; therefore, much of the
material becomes entrapped in the macropinosome [4–7].
In fact, Pan et al. published a report on their attempt at
reprogramming human ﬁbroblast cells using TAT fusion
recombinant proteins, which was unsuccessful even with the
help of an endosomal acidiﬁcation inhibitor, chloroquine
and an endosome-disruptive peptide, and hemagglutinin-2
subunit (HA2) [8]. Also, it is reported thatmethanol ﬁxation
causes permeabilization of cell membranes and results in the
artiﬁcial import of PTD-fused proteins [9].
We focused on developing the transduction technology
of proteins using the 30-amino acid peptide/transporter, Wr-
T, which has an enlarged hydrophobic pocket fused with
nine D-enantiomer polyarginines via a Gly-Pro-Gly spacer
[10]. To permit the eﬃcient escape of proteins from the
endosome, we used cationic lipids to enhance the proton
sponge or endosome buﬀering eﬀect, which is thought to
induceosmoticswellingandtheconsequentialruptureofthe
endosome [11].
In this study, we developed a protein transduction
methodthatcanbeculturedcontinuouslyforadherentliving
cells using both a functionally reinforced peptide transporter
and commercially available cationic lipid reagents.
2.MaterialsandMethods
2.1. Peptide Synthesis, Plasmid Contrast and Reagents. Wr-T
peptide was synthesized at Operon Biotechnologies by Fmoc
solid-phase peptide synthesis. Crude peptide was puriﬁed
by reverse-phase high-performance liquid chromatography
(purity: 82.6%). Peptide identity was conﬁrmed by mass
spectrometry.2 Journal of Biomedicine and Biotechnology
VENUS DNA was kindly provided by Dr. A. Miyawaki.
Protein expression plasmids were constructed using pEW-
destination vectors and a Gateway entry clone by the
Gateway LR recombination reaction (Invitrogen Life Tech-
nologies). The cationic lipid reagents used for protein trans-
duction included FuGENE6 (Roche Diagnostics), Lipofec-
tamine LTX (Invitrogen Life Technologies) and MultiFectam
(Promega) in DNA transfection reagent, and prodeliverIN
(OZ Biosciences) and BioPORTER (Genlantis) in protein
delivery reagent.
2.2. Expression and Puriﬁcation of Fusion Proteins. Auto-
mated protein in vitro synthesizer Protemist DT (Cell Free
Science) synthesized proteins using a wheat germ cell-free
system and bilayer reaction. The various expression vectors
were transcribed and translated to proteins automatically.
Column aﬃnity puriﬁcation is also conducted available for
purifying synthesized GST- or His-tagged fusion proteins
by the use of the Protemist DT. Placing Glutathione 4B
(GE Healthcare) or Ni-sepharose high performance (GE
Healthcare) resin in each column, translation reaction mix-
ture was applied to the column. Making wash buﬀer (GST;
Phosphate buﬀered saline, His; 20mM Na-phosphate pH7.5,
0.3M NaCl, 20mM imidazole) pass through the column,
puriﬁed proteins were eluted by elution buﬀer (GST; 50mM
Tris-HCl, 10mM reduced glutathione, pH8.0, His; 20mM
Na-phosphate pH7.5, 0.3M NaCl, 500mM imidazole). The
puriﬁed proteins conﬁrmed using SDS-PAGE.
2.3. Transduction of Fusion Proteins. HeLa and MRC-5 cells
were cultured in DMEM containing 10% fetal bovine serum
(FBS) and antibiotics (100U/mL penicillin, 100mg/mL
streptomycin) at 37◦C in an incubator with 5% CO2.T o
determine the intracellular localization of fusion proteins,
HeLa cells were ﬁrst grown in 24-well plates. Then, Wr-
Tp e p t i d e( 3 µM) and the cargo protein (1-2µg) were
mixed in 100µL of PBS at room temperature for 15min,
and then cationic lipid reagents were added as follows:
FuGENE6, 1.5µL; Lipofectamine LTX, 1µL; MultiFectam,
10µL; ProdeliverIN, 1.5µL; BioPORTER, 2.5µL. The solu-
tion was incubated at room temperature for 15min and
overlaid onto the cells, which had been aspirated and washed
once with PBS before use. Serum-free medium (100µL)
was added, and cells were incubated at 37◦Ci n5 %C O 2
for 3h. Intracellular localization of transduction proteins
was visualized in living cells by an inverted ﬂuorescence
microscope (Olympus IX51).
2.4. Cell Viability Assay. Cell viability was evaluated with
CellTiter-Glo Luminescent Cell Viability Assay (Promega)
to determine the number of metabolically active cells in
the culture based on quantitation of the ATP present. The
reagent was used according to the manufacturer’s protocol.
3. Results andDiscussion
3.1. Properties of Wr-T and Cationic Lipid Reagents for Protein
Transduction. A previous study demonstrated that Wr-T
induced the intracellular incorporation of cargo protein
in ﬁxed cells [12]. To conﬁrm that Alexa-488-labeled BSA
protein indeed diﬀused throughout the cytoplasm, the
localization of BSA was compared to that of LysoTracker Red
Lysosomal Probe (Lonza) for endocytotic vesicles in living
cells. Both BSA and the marker appeared in vesicular struc-
tures (Figure 1(a)). No BSA was detected in the cytoplasm,
which indicated that it was entrapped within the endosomal
vesicles. Therefore, we hypothesized that BSA could escape
from endocytotic vesicles if the proton sponge eﬀects of Wr-
T/BSA complexes were increased by the addition of cationic
lipids.
To characterize the functions of commercially available
cationic lipid reagents for protein transduction, we inves-
tigated the localization of BSA in living HeLa and MRC-
5 cells (Figures 1(b) and S1A of supplementary material
available at doi: 10.1155/2011/872065). Wr-T/FuGENE6,
Wr-T/ProdeliverIN, and Wr-T/BioPORTER mixtures of BSA
appeared in punctuate vesicular structures, and it was
suggested that these cationic lipid reagents did not induce
the escape of BSA from endosomes. In contrast, we observed
dramatic uptake and distribution of BSA throughout the
cytoplasm of each HeLa cell when Wr-T/MultiFectam and
Wr-T/Lipofectamine LTX mixtures were used. Moreover,
BSA was transduced less eﬃc i e n t l yb yM u l t i F e c t a mo r
Lipofectamine LTX used alone. Thus, a mixture of Wr-T and
cationic lipid reagents (MultiFectam or Lipofectamine LTX)
was required to eﬀectively enhance cell permeability and
endosomeescapeofBSA.Similarresultswereobservedwhen
Alexa-555-labeled ovalbumin protein mixed with Wr-T and
cationic lipid reagents were transduced into living cells.
Inmanycases,proteintransductiontechnologygenerates
toxicity via the transfection carrier. Thus, we compared
the degree of toxicity of Wr-T and cationic lipid reagents
mixtures in living cells. The cationic lipid reagents had low
toxicity, while cell viability was increased by the Wr-T and
cationic lipid reagents mixture (Figure 1(c)).
3.2. Wr-T and Cationic Lipid Reagents Mixture Eﬀectively
Diﬀused GST and FLAG Tag-Fused VENUS throughout
the Cytoplasm. We determined whether VENUS proteins
(variants of yellow ﬂuorescent protein) were delivered into
HeLa cells. VENUS expression vectors were used to produce
VENUS protein with a polyhistidine tag at the C-terminus
(3H-VENUS). The soluble fractions of the recombinant
VENUS proteins were puriﬁed on a Ni Sepharose column
(Figure 2(a)). Even with a mixture of Wr-T and cationic
lipidreagents,3H-VENUSwaspoorlydeliveredintothecells.
Furthermore, we detected aggregate ﬂuorescence, which
mighthaveoccurredbecause3H-VENUS,Wr-Tandcationic
lipid reagents partly form unstable complexes such as large
aggregates(Figure 2(b)). It is therefore reasonable to propose
that Wr-T and cationic lipid reagents mixtures would not
be able to deliver all proteins into the cells. Therefore, we
devised a cargo protein fused with glutathione S-transferase
(GST) and FLAG tag to promote stable association and not
agglutination with Wr-T peptide and cationic lipid reagents.
We had previously conﬁrmed that GST and FLAG tag usedJournal of Biomedicine and Biotechnology 3
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Figure 1: Wr-T/cationic lipid reagent mixture-mediated delivery of BSA proteins into living cells. (a) Cellular localization of Wr-T/BSA
complexes. The internalization of Alexa-488-labeled BSA protein and marker dyes for endocytotic vesicles into HeLa cells was analyzed by
confocal laser scanning microscopy. (b) Functional properties of Wr-T/cationic lipid reagents mixture pertaining to protein transduction.
HeLa cells were cotreated by BSA with Wt-T and cationic lipid reagents in serum-free medium. After incubation for 3h, the cells were placed
in fresh medium and assessed at the same exposure time by ﬂuorescence microscopy. (c) Cytotoxicity of Wr-T/cationic lipid reagent/cargo
protein mixture. HeLa cell viability was quantiﬁed by the amount of ATP derived from metabolically active cells. Data were consistent in two
repeat experiments.4 Journal of Biomedicine and Biotechnology
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Figure 2: Wr-T/cationic lipid reagents mixture-mediated delivery of VENUS proteins into living cells. (a, c) Following protein puriﬁcation,
3  His tag-VENUS, 3 GST and FLAG tag-VENUS, 3 mCherry and His tag-VENUS, and 3 mKG and His tag-VENUS were analyzed by SDS-
PAGE. VENUS proteins were complexed with Wr-T and cationic lipid reagents and then overlaid onto HeLa cells in a serum-free medium.
Cellular localization was monitored at the same exposure time by ﬂuorescence microscopy. (b) 3 His tag-VENUS; (c) 3 GST and FLAG
tag-VENUS; (e) 3 mCherry tag-VENUS and 3 mKG tag-VENUS.
together increased the solubility and stability of expressed
proteins, compared with GST tag alone.
We produced VENUS protein with GST and FLAG tag
at the C terminus (3GF-VENUS) using a wheat germ
cell-free protein synthesis system. The soluble fractions
of the recombinant VENUS proteins were puriﬁed on a
glutathione-Sepharose aﬃnity column (Figure 2(a)). 3GF-
VENUS migrated into HeLa cells and diﬀused throughout
the cytoplasm with a mixture of Wr-T and MultiFectam or
Lipofectamine LTX (Figure 2(c)). In addition, the mixture of
Wr-T and BioPORTER markedly enhanced the cytoplasmic
localization of 3GF-VENUS, unlike the case of BSA. We
questioned whether these results were truly dependent on
GST and FLAG tag, or whether they were due to variation
in molecular weight. Thus, we evaluated the delivery of
two diﬀerent tag-fused VENUS proteins, mCherry tag, and
mKGtag,whichhavemolecularweightsapproximatelyequal
to those of GST and FLAG tag (Figure 2(d)). Virtually
none of the Venus-mCherry and VENUS-mKG proteins
with Wr-T and BioPORTER were able to enter the cells
(Figure 2(e)), and little ﬂuorescence was observed through-
out the cytoplasm. Taken together, these data indicated thatJournal of Biomedicine and Biotechnology 5
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Figure 3:Wr-T/cationiclipidreagentsmixture-mediatedselectivedeliveryofproteinsintolivingcells.(a)3 GSTandFLAGtag-NLSVENUS
proteins were incubated with Wr-T and cationic lipid reagents and then overlaid onto HeLa cells in serum-free medium for 3h. The cells
were then washed and observed at the same exposure time by ﬂuorescence microscopy. (b) The cells treated with Wr-T/BioPORTER mixture
were counterstained with Hoescht 33342.
when VENUS protein is fused with GST and FLAG tag, they
associate through noncovalent interactions with Wr-T and
BioPORTER and form stable complexes.
3.3. GST and FLAG Tag-Fused VENUS Proteins/Wr-T/
Cationic Lipid Reagent Complexes Can be Selectively Delivered
to the Nucleus by Combining NLS Peptides. To test whether
a VENUS protein with nuclear transport signal (NLS) can
be selectively delivered to the nucleus, we produced VENUS
protein fused with NLS at the N terminus and GST and
FLAG tag at the C terminus (3GF-NLS VENUS) in the same
wayasthe3GS-VENUSproteins.The3GF-NLSVENUS/Wr-
T/BioPORTER complexes were delivered to the nucleus
in >90% of Hela cells (Figures 3(a) and 3(b)). On the
other hand, <30% of the cells exhibited localization to
the nucleus with Wr-T/MultiFectam or Lipofectamine LTX
complexes. Similar results were shown in the case of MRC-
5 cells (Figure S1B of supplementary material available at
doi:10.1155/2011/872065). Wewereunabletodetectnuclear
VENUS ﬂuorescence with MultiFectam or Lipofectamine
LTX alone. Our ﬁndings showed that GST and FLAG tag-
fused cargo proteins can be selectively delivered to the
nucleus by using NLS peptides with Wr-T and cationic lipid
reagents. Furthermore, our results imply that by fusing high
stability proteins such as GST and FLAG tag, cargo proteins
agglutinated or not associated with Wr-T and cationic lipid
reagents could form stable complexes with them and be
delivered into the target organelles.
In conclusion, we described a strategy for the delivery
of full-length proteins into living cells, based on association
withWr-Tandcationiclipidreagents.Thisallowedthedeliv-
ery of distinct proteins into the living cells and escape from
the endosomal vesicles, without the need for crosslinking or
denaturation steps. This strategy is expected to be a useful
tool for studying the role of proteins and protein-protein
interactions in living cells, as well as cell reprogramming
using recombinant proteins. This strategy may also be a
potential clinical tool for tissue engineering and regenerative
medicine.
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